Adeno-Associated Virus– tag –
-
Yeasen and Porton Advanced Form Strategic Alliance to Fortify CGT Supply Chain and Drive Innovation
Company Announcement China Overview Yeasen Biotechnology and Porton Advanced Solutions have established a strategic partnership aimed at fortifying the cell and gene therapy (CGT) supply chain and fostering innovation. The alliance will ... -
Oxford Biomedica Launches Fast-Track Viral Vector Service, Accelerating Gene Therapy Development by Cutting Manufacturing Times by up to 8 Months
Kalkine UK Overview Oxford Biomedica has launched a fast-track viral vector service to accelerate gene therapy development. This new service shortens GMP-grade manufacturing for AAV vectors from approximately 15 months to as little as 7 ... -
Cracking the Cost Code: Cellares’ Automated Platform Targets 75% Reduction in CAR-T Manufacturing, Pinpointing Viral Vectors as Key Driver
IntuitionLabs USA Overview A new analysis highlights viral vectors as the primary cost driver in CAR-T cell therapy manufacturing, prompting an urgent need for more efficient production. While existing closed-system platforms offer incre... -
Gene Therapy’s Backbone: Oxford Biomedica Acquires ABL Europe, Driving Consolidation in Viral Vector Manufacturing
Industry News UK Overview The viral vector manufacturing market, crucial for gene therapy commercialization, is experiencing accelerated consolidation driven by M&A, exemplified by Oxford Biomedica's acquisition of ABL Europe. This s... -
AGC Biologics Accelerates Cell & Gene Therapy Commercialization with Expanded Viral Vector Manufacturing Platforms
Facebook (AGC Biologics page) USA Overview AGC Biologics is significantly expanding its specialized viral vector manufacturing services for the rapidly growing cell and gene therapy (CGT) sector. The company now offers comprehensive adhe... -
APAC’s Biomanufacturing Ascent: Australia Pioneers Viral Vector Production for Gene Therapies
Industry Publication Australia Overview The Asia-Pacific (APAC) region is rapidly accelerating its specialized manufacturing capabilities for high-value modalities like viral vectors and cell therapies, moving beyond traditional API prod... -
Gene Therapy’s Production Puzzle: Why AAV Outscales Lentiviral Vectors in Large-Scale Manufacturing
Industry Analysis USA Overview A recent analysis comparing AAV and lentiviral vector manufacturing platforms, both produced via transient transfection of HEK293 cells, reveals critical downstream manufacturing distinctions. AAV's stable ... -
Gene Therapy Manufacturing: Viral Vector CDMOs Confront Oversupply Amidst Rapid Expansion
IntuitionLabs USA Overview A recent industry report offers a comparative analysis of the AAV and lentiviral vector CDMO market, revealing trends of consolidation and emerging capacity oversupply. It highlights key players like FUJIFILM D... -
Cell & Gene Therapy Manufacturing Faces Deepening Bottlenecks: AmplifyBio, Exothera Close; Thermo Fisher Cuts Viral Vector Jobs, but FDA Eases Regulations to Support Growth
Endpoints News Global Overview Despite cell and gene therapies becoming a commercial reality, manufacturing remains the primary bottleneck. The CDMO sector is struggling with overcapacity and underfunding, leading to closures like Amplif... -
OXB Accelerates Gene Therapy Production for Plowshare Therapies, Leveraging FDA-Approved AAV Manufacturing in North Carolina
Markets Insider UK Overview OXB has partnered with Plowshare Therapies to provide crucial process development and GMP manufacturing for Plowshare’s AAV gene therapy program. This collaboration leverages OXB's FDA-approved commercial-scal...
